India world's largest Vaccine producer and global supplier by volume: MoS (See 'Corp Brief') PBPT - Transfer of funds by beneficial owner to purchase properties in names of relatives without demonstrable loan agreements or independent source of income is classic benami transaction under the Act: SAFEMA Tribunal (See 'Legal Desk') Mizoram's Railway Lifeline completes One Year of Success (See 'Corp Brief') FEMA - Financial difficulties do not excuse non-compliance with mandatory FEMA requirements - Funds received via FDI cannot be utilised or diverted for purposes other than those for which they were received: SAFEMA Tribunal (See 'Legal Desk') Expanding coal production and infrastructure while widening opportunities in Central India (See 'Corp Brief') FEMA - Penalties under FEMA are civil in nature & may be imposed for technical or procedural contraventions without requiring proof of mens rea: SAFEMA Tribunal (See 'Legal Desk') Cochin Shipyard Ltd and Drydocks World Form JV To strengthen India's Ship Repair Industry (See 'Corp Brief') FEMA - Non-issue of shares against the full amount of FDI received constitutes contravention of applicable provisions of FEMA & regulations framed thereunder: SAFEMA Tribunal (See 'Legal Desk') Next Subscription Economy may arrive with Telecos monthly bills (See CORP EINSICHT) BRICS Bharat Innovates Exposition: 37 Indian Deep Tech Innovators participating (See 'Corp Brief') India's Coastline offers significant Potential for Marine Resources MoS (See 'Corp Brief') State Govets should assess current utilisation of cess funds: Mandaviya (See 'Corp Brief') Union Minister to participate in G20 Energy Abundance Ministerial Meeting in Houston (See 'Corp Brief') BEE showcases Electric Cooking Solutions for transition from LPG to Electricity (See 'Corp Brief') SARFAESI - Section 14(2) enables secured creditor to seek compliance with possession order - writ remedy not maintainable where this option is not exhausted first: HC (See 'Legal Desk') Dryland Congress 2026: Breeding, Climate Resilience and Nutrition take Centre Stage on Day One (See 'Corp Brief') MoS inaugurates Technology Centre at Devanahalli, Bengaluru (See 'Corp Brief') FEMA - Penalty cannot be imposed on company for delayed submission of Form FC-GPR where delay is entirely attributable to negligence & admitted administrative failure of its authorised dealer bank in transmitting timely submitted documents to RBI: SAFEMA (See 'Legal Desk') ASEAN and India advance cooperation on Climate-Resilient Agriculture & Digital Innovation (See 'Corp Brief') Bihar and West Bengal to inaugurate Labour Chowk-cum-Facilitation Centres (See 'Corp Brief') Companies Act - Issuance of order by a central authority stationed in New Delhi does not, per se, confer territorial jurisdiction or constitute a substantial part of cause of action when underlying subject matter has its closest nexus with another jurisdiction: HC (See 'Legal Desk') Digital India BHASHINI advances Multilingual AI for Inclusive Digital Governance (See 'Corp Brief') India must leverage Latest Technologies for Forest Assessment: Yadav (See 'Corp Brief') Trade Marks - Order rejecting registration of trade marks is invalid where no reasoning whatsoever is given, thereby showing complete non-application of mind: HC (See 'Legal Desk') MoS lays bricks for BEDF Basmati and Organic Training Centre in Pilibhit (See 'Corp Brief') DRI seizes 740 kg cannabis and charas in operations across country (See 'Corp Brief') Competition Act - Allegations of anti-competitive agreements and abuse of dominant position cannot be sustained on basis of information which is generic, speculative, lacking in foundational facts & not backed by cogent evidence: CCI (See 'Legal Desk')

Print

MoS reaffirms India's commitment to global pharmaceutical standardization

Published: Feb 06, 2025

By TIOLCorplaws News Service

NEW DELHI, FEB 06, 2025: UNION Minister of State for Health and Family Welfare, Anupriya Patel delivered the keynote address at the 15th International Meeting of World Pharmacopoeias (IMWP), hosted by the Indian Pharmacopoeia Commission (IPC) under the aegis of the Ministry of Health and Family Welfare, Government of India, in collaboration with the World Health Organization (WHO), here today. The meeting brought together global pharmacopoeial leaders, regulatory authorities, and industry stakeholders to deliberate on key issues related to pharmaceutical standards and harmonization.

Addressing the gathering, Patel reaffirmed India's commitment to global pharmaceutical standardization and regulatory convergence. She highlighted India's role as the "Pharmacy of the World" and emphasized the importance of ensuring access to high-quality medicines globally. She stated that the IMWP serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization.

On this occasion, the Union Minister also released the IPC Newsletter 2024 and a special IPC video film, which showcase India's advancements in pharmacopoeial science and the Commission's efforts in ensuring high-quality pharmaceutical standards. The video film can be accessed at the following link: https://www.youtube.com/watch?v=MCdAZodvOSM .

Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, underscored the significance of global partnerships in strengthening pharmaceutical quality standards. She reiterated India's efforts in aligning regulatory frameworks with international best practices and ensuring the availability of safe and effective medicines worldwide.

Dr. Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director, IPC, and Drugs Controller General (India), highlighted IPC's contributions in setting global benchmarks in pharmacopoeial science. He elaborated on IPC's initiatives, including the IP Online platform, which enhances accessibility and usability of Indian Pharmacopoeia standards. He emphasized the role of scientific advancements and regulatory cooperation in shaping global pharmaceutical standards.

Dr. Roderico H. Ofrin, WHO Representative to India, commended India's leadership in pharmacopoeial standard-setting and emphasized the importance of regulatory harmonization in ensuring patient safety and public health.

The 15th IMWP is set to facilitate discussions on key focus areas, including:

- Updates on recommendations from the 14th IMWP and review of progress on harmonization initiatives.

- Emerging issues in impurity assessment (Q3) and the implications of ICH Q6 guidelines on pharmacopoeial monograph specifications.

- Defining the IMWP Charter to establish a long-term governance structure for the forum.

- Enhancing collaboration among global pharmacopoeias and regulatory bodies, with updates from the Pharmacopoeial Discussion Group (PDG).

- Promotion of environmental sustainability in pharmacopoeial practices and pharmaceutical manufacturing standards.

- Finalization of reports for the 15th IMWP and preparatory discussions for the 16th IMWP.

The deliberations during the IMWP will reinforce the role of pharmacopoeias in ensuring the quality, safety, and efficacy of medicines. The outcomes of the meeting will guide future collaborations in standard-setting and regulatory harmonization.

The 15th IMWP, which commenced today, will conclude on 7th February 2025. The discussions held over these three days will set the stage for further strengthening global pharmacopoeial cooperation and enhancing pharmaceutical quality assurance.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.